$SGMO
Sangamo Therapeutics Inc

2018 Q2 Form 10-Q Financial Statement

#000156459018020536 Filed on August 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $21.42M $8.253M
YoY Change 159.49% 122.93%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.30M $6.040M
YoY Change 87.09% -45.54%
% of Gross Profit
Research & Development $29.26M $14.98M
YoY Change 95.29% -23.0%
% of Gross Profit
Depreciation & Amortization $600.0K $300.0K
YoY Change 100.0% 0.0%
% of Gross Profit
Operating Expenses $40.56M $21.02M
YoY Change 92.93% -31.18%
Operating Profit -$19.14M
YoY Change
Interest Expense $2.500M $280.0K
YoY Change 792.86% 16.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$16.64M -$12.49M
YoY Change 33.23% -53.05%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$16.64M -$12.49M
YoY Change 33.22% -53.0%
Net Earnings / Revenue -77.7% -151.35%
Basic Earnings Per Share
Diluted Earnings Per Share -$171.1K -$172.2K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $539.4M $249.9M
YoY Change 115.86% 45.04%
Cash & Equivalents $59.41M $69.84M
Short-Term Investments $480.0M $180.1M
Other Short-Term Assets $5.100M $2.000M
YoY Change 155.0% 53.85%
Inventory
Prepaid Expenses
Receivables $5.000M $3.500M
Other Receivables $500.0K $300.0K
Total Short-Term Assets $550.0M $255.7M
YoY Change 115.1% 45.16%
LONG-TERM ASSETS
Property, Plant & Equipment $37.20M $8.300M
YoY Change 348.19% 174.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $34.20M $16.30M
YoY Change 109.82%
Other Assets $4.700M $1.000M
YoY Change 370.0% 584.93%
Total Long-Term Assets $77.70M $27.30M
YoY Change 184.62% 474.01%
TOTAL ASSETS
Total Short-Term Assets $550.0M $255.7M
Total Long-Term Assets $77.70M $27.30M
Total Assets $627.7M $283.0M
YoY Change 121.8% 56.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.40M $9.200M
YoY Change 56.52% 31.43%
Accrued Expenses $4.300M $2.900M
YoY Change 48.28% 31.82%
Deferred Revenue $57.22M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $75.90M $41.70M
YoY Change 82.01% 188.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $3.900M
YoY Change -100.0% 1850.0%
Other Long-Term Liabilities $163.9M $43.40M
YoY Change 277.65% 600.0%
Total Long-Term Liabilities $163.9M $47.30M
YoY Change 246.51% 639.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $75.90M $41.70M
Total Long-Term Liabilities $163.9M $47.30M
Total Liabilities $239.9M $89.00M
YoY Change 169.55% 326.18%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $387.9M $194.0M
YoY Change
Total Liabilities & Shareholders Equity $627.7M $283.0M
YoY Change 121.8% 56.43%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$16.64M -$12.49M
YoY Change 33.22% -53.0%
Depreciation, Depletion And Amortization $600.0K $300.0K
YoY Change 100.0% 0.0%
Cash From Operating Activities $122.4M $56.80M
YoY Change 115.49% -452.8%
INVESTING ACTIVITIES
Capital Expenditures -$3.200M -$1.700M
YoY Change 88.24% 1600.0%
Acquisitions
YoY Change
Other Investing Activities -$308.9M -$82.60M
YoY Change 273.97% 2073.68%
Cash From Investing Activities -$312.1M -$84.40M
YoY Change 269.79% 2064.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 218.4M 79.00M
YoY Change 176.46%
NET CHANGE
Cash From Operating Activities 122.4M 56.80M
Cash From Investing Activities -312.1M -84.40M
Cash From Financing Activities 218.4M 79.00M
Net Change In Cash 28.70M 51.40M
YoY Change -44.16% -357.0%
FREE CASH FLOW
Cash From Operating Activities $122.4M $56.80M
Capital Expenditures -$3.200M -$1.700M
Free Cash Flow $125.6M $58.50M
YoY Change 114.7% -465.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
480040000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
193482000
CY2018Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
34182000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
1012000
CY2018Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
57215000
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
28345000
CY2018Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
137731000
CY2017Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
29244000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
131000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16410000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1656000
us-gaap Share Based Compensation
ShareBasedCompensation
6564000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-465000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
322000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
32000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1634000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1477000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12542000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36696000
us-gaap Profit Loss
ProfitLoss
-36827000
us-gaap Profit Loss
ProfitLoss
-29123000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1207000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3564000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1039000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2733000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21416000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8253000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34053000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11678000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
91831000
CY2017Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-51000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
24000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1133000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2654000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
138474000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
64346000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
104307000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
43708000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
451240000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
159166000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
133297000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
83029000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5768000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2175000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-323711000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-78312000
sgmo Net Proceeds From Issuance Public Offering
NetProceedsFromIssuancePublicOffering
215756000
sgmo Net Proceeds From Issuance Public Offering
NetProceedsFromIssuancePublicOffering
81562000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
57000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
7000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13285000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
825000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
228984000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
82380000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9580000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
47776000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
53326000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22061000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
62906000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
69837000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.17%;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</p></div>
sgmo Cash Equivalent Maturity Period Highly Liquid Investment
CashEquivalentMaturityPeriodHighlyLiquidInvestment
three months or less
CY2018Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
514348000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
194749000
CY2018Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
110000
CY2018Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
236000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
255000
CY2018Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
514222000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
194494000
CY2018Q2 sgmo Cash Equivalents And Available For Sale Securities Amortized Cost
CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
571489000
CY2017Q4 sgmo Cash Equivalents And Available For Sale Securities Amortized Cost
CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
223634000
CY2018Q2 sgmo Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
111000
CY2018Q2 sgmo Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
236000
CY2017Q4 sgmo Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
255000
CY2018Q2 sgmo Cash Equivalents And Available For Sale Securities
CashEquivalentsAndAvailableForSaleSecurities
571364000
CY2017Q4 sgmo Cash Equivalents And Available For Sale Securities
CashEquivalentsAndAvailableForSaleSecurities
223379000
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2018Q2 sgmo Other Than Temporarily Impaired Investment
OtherThanTemporarilyImpairedInvestment
0
CY2017Q2 sgmo Other Than Temporarily Impaired Investment
OtherThanTemporarilyImpairedInvestment
0
sgmo Investments Maturity Dates Available For Sale Securities
InvestmentsMaturityDatesAvailableForSaleSecurities
P1Y
CY2018Q2 sgmo Cash Equivalents And Available For Sale Securities Mature Within Twenty Four Months
CashEquivalentsAndAvailableForSaleSecuritiesMatureWithinTwentyFourMonths
34200000
CY2014Q1 sgmo Number Of Research Program
NumberOfResearchProgram
2
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
sgmo Percentage Of Disallowance Of Entertainment Expense
PercentageOfDisallowanceOfEntertainmentExpense
1.00
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3514000
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1964000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6564000

Files In Submission

Name View Source Status
0001564590-18-020536-index-headers.html Edgar Link pending
0001564590-18-020536-index.html Edgar Link pending
0001564590-18-020536.txt Edgar Link pending
0001564590-18-020536-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sgmo-10q_20180630.htm Edgar Link pending
sgmo-20180630.xml Edgar Link completed
sgmo-20180630.xsd Edgar Link pending
sgmo-20180630_cal.xml Edgar Link unprocessable
sgmo-20180630_def.xml Edgar Link unprocessable
sgmo-20180630_lab.xml Edgar Link unprocessable
sgmo-20180630_pre.xml Edgar Link unprocessable
sgmo-ex109_61.htm Edgar Link pending
sgmo-ex311_9.htm Edgar Link pending
sgmo-ex312_8.htm Edgar Link pending
sgmo-ex321_10.htm Edgar Link pending
Show.js Edgar Link pending